Immunology and immunotherapy of human cancer: present concepts and clinical developments

被引:50
作者
Bremers, AJA [1 ]
Parmiani, G [1 ]
机构
[1] Ist Nazl Studio & Cura Tumori, Unit Immunotherapy Human Tumours, I-20133 Milan, Italy
关键词
immunology; immunotherapy; human cancer;
D O I
10.1016/S1040-8428(99)00059-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy of cancer is entering into a new phase of active investigation both at the pre-clinical and clinical level, This is due to the exciting developments in basic immunology and tumour biology that have allowed a tremendous increase in our understanding of mechanisms of interactions between the immune system and tumour cells, This review briefly summarizes the state of the art in basic tumour immunology before discussing the clinical applications of the new concepts in the clinical setting, Clinical approaches are diverse but can now be based on strong scientific rationales, The analysis of the available clinical results suggests that, despite some disappointments, there is room for optimism that both active immunotherapy (vaccination) and adoptive immunotherapy may soon become part of the therapeutic arsenal to combat cancer in a more efficient way, (C) 2000 Elsevier Science Ireland Ltd, All rights reserved.
引用
收藏
页码:1 / 25
页数:25
相关论文
共 228 条
[1]  
AbdelWahab Z, 1997, CANCER, V80, P401, DOI 10.1002/(SICI)1097-0142(19970801)80:3<401::AID-CNCR8>3.0.CO
[2]  
2-U
[3]   A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells [J].
Adema, GJ ;
Hartgers, F ;
Verstraten, R ;
deVries, E ;
Marland, G ;
Menon, S ;
Foster, J ;
Xu, YM ;
Nooyen, P ;
McClanahan, T ;
Bacon, KB ;
Figdor, CG .
NATURE, 1997, 387 (6634) :713-717
[4]   T-CELL PRIMING VERSUS T-CELL TOLERANCE INDUCED BY SYNTHETIC PEPTIDES [J].
AICHELE, P ;
BRDUSCHARIEM, K ;
ZINKERNAGEL, RM ;
HENGARTNER, H ;
PIRCHER, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :261-266
[5]   Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].
Albert, ML ;
Sauter, B ;
Bhardwaj, N .
NATURE, 1998, 392 (6671) :86-89
[6]   Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver [J].
Alexander, HR ;
Bartlett, DL ;
Libutti, SK ;
Fraker, DL ;
Moser, T ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1479-1489
[7]   Intraperitoneal radioimmunotherapy of ovarian cancer with Lu-177-CC49: A phase I/II study [J].
Alvarez, RD ;
Partridge, EE ;
Khazaeli, MB ;
Plott, G ;
Austin, M ;
Kilgore, L ;
Russell, CD ;
Liu, TP ;
Grizzle, WE ;
Schlom, J ;
LoBuglio, AF ;
Meredith, RF .
GYNECOLOGIC ONCOLOGY, 1997, 65 (01) :94-101
[8]  
Anichini A, 1996, J IMMUNOL, V156, P208
[9]   ADOPTIVE IMMUNOTHERAPY OF ADVANCED MELANOMA PATIENTS WITH INTERLEUKIN-2 (IL-2) AND TUMOR-INFILTRATING LYMPHOCYTES SELECTED INVITRO WITH LOW-DOSES OF IL-2 [J].
ARIENTI, F ;
BELLI, F ;
RIVOLTINI, L ;
GAMBACORTIPASSERINI, C ;
FURLAN, L ;
MASCHERONI, L ;
PRADA, A ;
RIZZI, M ;
MARCHESI, E ;
VAGLINI, M ;
PARMIANI, G ;
CASCINELLI, N .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (05) :315-322
[10]   Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells [J].
Arienti, F ;
SuleSuso, J ;
Belli, F ;
Mascheroni, L ;
Rivoltini, L ;
Melani, C ;
Maio, M ;
Cascinelli, N ;
Colombo, MP ;
Parmiani, G .
HUMAN GENE THERAPY, 1996, 7 (16) :1955-1963